A detailed history of Oberweis Asset Management Inc transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Oberweis Asset Management Inc holds 366,200 shares of DVAX stock, worth $4.66 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
366,200
Previous 331,300 10.53%
Holding current value
$4.66 Million
Previous $3.72 Million 9.65%
% of portfolio
0.22%
Previous 0.24%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $11.61 $350,745 - $405,189
34,900 Added 10.53%
366,200 $4.08 Million
Q2 2024

Aug 14, 2024

SELL
$10.73 - $12.58 $1.41 Million - $1.65 Million
-131,400 Reduced 28.4%
331,300 $3.72 Million
Q1 2024

May 15, 2024

BUY
$11.7 - $14.98 $530,010 - $678,594
45,300 Added 10.85%
462,700 $5.74 Million
Q4 2023

Feb 14, 2024

BUY
$13.09 - $14.98 $421,498 - $482,356
32,200 Added 8.36%
417,400 $5.84 Million
Q3 2023

Nov 14, 2023

BUY
$12.64 - $14.99 $1.77 Million - $2.1 Million
139,800 Added 56.97%
385,200 $5.69 Million
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.17 $674,725 - $902,145
68,500 Added 38.72%
245,400 $3.17 Million
Q1 2023

May 15, 2023

SELL
$9.44 - $11.88 $64,192 - $80,784
-6,800 Reduced 3.7%
176,900 $1.74 Million
Q4 2022

Feb 14, 2023

BUY
$10.27 - $13.29 $403,611 - $522,296
39,300 Added 27.22%
183,700 $1.95 Million
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $71,496 - $125,568
7,200 Added 5.25%
144,400 $1.51 Million
Q2 2022

Aug 15, 2022

BUY
$7.45 - $12.83 $236,910 - $407,994
31,800 Added 30.17%
137,200 $1.73 Million
Q1 2022

May 16, 2022

BUY
$9.75 - $14.44 $254,475 - $376,884
26,100 Added 32.91%
105,400 $1.14 Million
Q4 2021

Feb 14, 2022

BUY
$13.17 - $20.94 $280,521 - $446,022
21,300 Added 36.72%
79,300 $1.12 Million
Q3 2021

Nov 15, 2021

BUY
$9.16 - $19.83 $531,280 - $1.15 Million
58,000 New
58,000 $1.11 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.61B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Oberweis Asset Management Inc Portfolio

Follow Oberweis Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oberweis Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oberweis Asset Management Inc with notifications on news.